10 September 2013

Piramal | Healthcare to invest $11 million at its Morpeth, UK facility

Morpeth, England - 10 September 2013 - Piramal | Healthcare is to invest US$11 million at its Morpeth, UK facility to triple the production capacity for hormonal products, including contraceptive pills and hormone replacement therapies. The expansion will see the Morpeth site's production capacity increase by around 2 billion tablets per annum. Work on the new suite, which will house formulation, packaging coating and tableting equipment, will commence at the end of 2013, with mechanical completion anticipated within 12 months and full operations expected to begin following a 6 month validation period.

"The production of hormonal products is a highly specialised, niche area," commented Piramal Enterprises' Executive Director and COO, Vijay Shah. "The Morpeth facility is our Centre of Excellence for these products and this expansion will greatly enhance our offer and potential for growth in this space. The hormonal sector currently represents a USD 11 billion market globally and is growing at a pace of 4% to 5% annually. With major competition limited to a small number of CMOs in Europe, Piramal sees major opportunities for growth in this area given our vast experience in this field, which spans more than 40 years."

With this expansion, Piramal aims to be one of the largest contract manufacturers in this niche segment which, as per the USFDA and MHRA regulations, requires a dedicated manufacturing facility for the handling of high potent molecules. The 13,000 sq ft Morpeth facility also houses Active Pharmaceutical Ingredient (API) production, general solid formulation production, and a range of clinical trial supply and research facilities, and was acquired by Piramal from Pfizer in 2006. 

Piramal | Healthcare is a part of the Piramal Enterprises Ltd, a diversified Indian conglomerate led by Ajay G. Piramal. 

Source: Piramal Enterprises Ltd.